BeOne Medicines Ltd. - Sponsored ADR (ONC)
(Delayed Data from NSDQ)
$298.52 USD
-8.71 (-2.84%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $298.88 +0.36 (0.12%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ONC 298.52 -8.71(-2.84%)
Will ONC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ONC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ONC
BeOne Medicines Ltd. - Sponsored ADR (ONC) Reports Q2 Earnings: What Key Metrics Have to Say
Stevanato (STVN) Soars 10.0%: Is Further Upside Left in the Stock?
ONC: What are Zacks experts saying now?
Zacks Private Portfolio Services
BeOne Medicines Ltd. - Sponsored ADR (ONC) Surges 4.0%: Is This an Indication of Further Gains?
Compared to Estimates, BeiGene (ONC) Q1 Earnings: A Look at Key Metrics
Community Health Q1 Earnings Top on Rising Patient Volumes, Stock Up 8%
Other News for ONC
BeOne Medicines Ltd. 2025 Q2 - Results - Earnings Call Presentation
BeOne Medicines Ltd. (ONC) Q2 2025 Earnings Call Transcript
BeOne Medicines outlines $5B–$5.3B 2025 revenue target as BRUKINSA leads BTK market and global expansion accelerates
Decoding BeOne Medicines Ltd (ONC): A Strategic SWOT Insight
BeOne Medicines beats top-line and bottom-line estimates; updates FY guidance